Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency
Status:
Withdrawn
Trial end date:
2018-03-06
Target enrollment:
Participant gender:
Summary
This phase II study will assess the effect of a treatment combination of Rituximab and
azathioprine in patients with Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD)
compared to placebo, based on change in lung function at 18 months compared to baseline. The
researchers will also assess if the drugs improved quality of life.